Panretin
NDC Package 62856-601-22

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Panretin is a medication used to treat skin sores in patients with a certain type of AIDS-related cancer (Kaposi's sarcoma). Marketed by Eisai Inc., this product is identified by NDC 62856-601 and is authorized under FDA application NDA020886.

Identification & Billing

NDC Package Code
62856-601-22
Package Description
60 g in 1 TUBE
Product Code
62856-601
11-Digit Billing Format
62856060122
Billing Unit
GM - Billing unit of "gram" is used when a product is measured by its weight.
Units Per Package
60 GM

Clinical Specifications

Proprietary Name
Panretin
Dosage Form
-
Usage Information
This medication is used to treat skin sores in patients with a certain type of AIDS-related cancer (Kaposi's sarcoma). Alitretinoin belongs to a class of medications called retinoids. It works by affecting the growth of skin cells. This medication should not be used when medications taken by mouth are needed to treat the Kaposi's sarcoma (for example, if you have had more than 10 new skin sores in the previous month, or if the disease affects the lungs or other organs).

Regulatory & Marketing

Labeler Name
Eisai Inc.
FDA Application #
NDA020886
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
02-03-2009
End Marketing Date
10-31-2021
Listing Expiration
10-31-2021
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 62856-601-22 identifies a specific commercial package of 60 g in 1 tube of Panretin, labeled by Eisai Inc.. This product is billed per "GM" gram and contains an estimated amount of 60 billable units per package. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Eisai Inc. on February 03, 2009. The current certification is valid through October 31, 2021.

What are the primary indications for this medication?

This medication is used to treat skin sores in patients with a certain type of AIDS-related cancer (Kaposi's sarcoma). Alitretinoin belongs to a class of medications called retinoids. It works by affecting the growth of skin cells. This medication should not be used when medications taken by mouth are needed to treat the Kaposi's sarcoma (for example, if you have had more than 10 new skin sores in the previous month, or if the disease affects the lungs or other organs).

How is this Eisai Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 62856060122. Quantities are measured in per "gm or gram", products billed per gram are products measured by weight.. There are 60 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
62856-601-22
11-Digit CMS (5-4-2)
62856-0601-22

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.